Read the full announcement in PDF Attachment 2022_24_Financial_calendar_2023
PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a…
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation…
TUCSON, Ariz., June 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing…
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE…
Medicare Advantage company to also introduce its award-winning health plans to new counties within Arizona, California, Nevada and North Carolina, pending…
Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2…
Leading radiologists to highlight clinical examples demonstrating power of iCAD’s complete suite of ProFound AI Breast Health SolutionsNASHUA, N.H., June…
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain…
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trialSOUTH SAN FRANCISCO,…